According to reports from multiple media sources,Liu Ming, Vice President of AstraZeneca China and Head of the Oncology Lung Cancer Business Unit, has decided to leave AstraZeneca China due to personal development reasons.Information about Liu Ming can no longer be found on the AstraZeneca China official website.

Liu Ming joined AstraZeneca in August 2022. Over the past year,He led the team to consolidate the market share of "Tagrisso", expand its adjuvant indications, maintain the top position in China's lung cancer business market share, and successfully include "Orpathys" in the medical insurance directory.And rapid expansion and hospital access after landing.

At the same time, AstraZeneca also announced Liu Ming's successor.

Jian Shi Ju learned that,Zhang Lingyan, former General Manager of Pfizer's Vaccine Division, will join AstraZeneca on December 1st as Vice President of China and Head of the Oncology and Lung Cancer Division.

As a veteran of AstraZeneca, Zhang Lingyan has many years of work experience in the pharmaceutical field and has held various positions at multinational companies such as Pfizer and Merck. From 2006 to 2013, she worked at AstraZeneca as the Sales Director for Oncology in the Southwest Region.

Author: Xiaomi

Editor | Jiang Yun, Jia Ting

Operation | Twenty-thirteen

Statement: Original content by Jian Shi Ju, please do not reprint without permission.

"Can Evergrande New Glory deliver on its promise of a 'sales peak of 5 billion yuan'?"

Hu Jinglin, the first director of the National Healthcare Security Administration, appointed as the Party Secretary of the State Taxation Administration

Philips Issues Level 1 Recall for Three MRI Products!